Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bertheau

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Clinical Pathology|August 26, 1998
Variability of immunohistochemical reactivity on stored paraffin slidesP Bertheau, D Cazals-Hatem, V Meignin, et al.
Gastroenterologie Clinique Et Biologique|January 1, 1993
[Fatal fulminant hepatitis induced by nilutamide (Anandron)]P Pescatore, P Hammel, F Durand, et al.
The Journal of Pathology|August 28, 2001
Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactionsL Ma, A de Roquancourt, P Bertheau, et al.
Lancet (London, England)|September 24, 2002
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapyP Bertheau, F Plassa, M Espié, et al.
British Journal of Cancer|November 11, 1999
The effects of transurethral resection and cystoprostatectomy on dissemination of epithelial cells in the circulation of patients with bladder cancerF Desgrandchamps, M Teren, L Dal Cortivo, et al.
British Journal of Cancer|January 13, 2006
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?L Arnould, M Gelly, F Penault-Llorca, et al.
The British Journal of Dermatology|April 14, 2019
PAPASH, PsAPASH and PASS autoinflammatory syndromes: phenotypic heterogeneity, common biological signature and response to immunosuppressive regimensJ Gottlieb, M Madrange, C Gardair, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2018
Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancerDavid Groheux, L Biard, J Lehmann-Che, et al.
British Journal of Cancer|September 19, 2007
Changes in allelic imbalances in locally advanced breast cancers after chemotherapyM Varna, H Soliman, J-P Feugeas, et al.
British Journal of Cancer|February 27, 2014
Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimenS Giacchetti, R Porcher, J Lehmann-Che, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Clinical Pathology|August 26, 1998
Variability of immunohistochemical reactivity on stored paraffin slidesP Bertheau, D Cazals-Hatem, V Meignin, et al.
Gastroenterologie Clinique Et Biologique|January 1, 1993
[Fatal fulminant hepatitis induced by nilutamide (Anandron)]P Pescatore, P Hammel, F Durand, et al.
The Journal of Pathology|August 28, 2001
Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactionsL Ma, A de Roquancourt, P Bertheau, et al.
Lancet (London, England)|September 24, 2002
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapyP Bertheau, F Plassa, M Espié, et al.
British Journal of Cancer|November 11, 1999
The effects of transurethral resection and cystoprostatectomy on dissemination of epithelial cells in the circulation of patients with bladder cancerF Desgrandchamps, M Teren, L Dal Cortivo, et al.
British Journal of Cancer|January 13, 2006
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?L Arnould, M Gelly, F Penault-Llorca, et al.
The British Journal of Dermatology|April 14, 2019
PAPASH, PsAPASH and PASS autoinflammatory syndromes: phenotypic heterogeneity, common biological signature and response to immunosuppressive regimensJ Gottlieb, M Madrange, C Gardair, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2018
Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancerDavid Groheux, L Biard, J Lehmann-Che, et al.
British Journal of Cancer|September 19, 2007
Changes in allelic imbalances in locally advanced breast cancers after chemotherapyM Varna, H Soliman, J-P Feugeas, et al.
British Journal of Cancer|February 27, 2014
Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimenS Giacchetti, R Porcher, J Lehmann-Che, et al.
Pageof 5